Sunshine Biopharma, Inc. (SBFM)
0.243
+0.01
(+2.84%)
USD |
NASDAQ |
Oct 14, 16:00
0.2298
-0.01
(-5.43%)
After-Hours: 05:18
Sunshine Biopharma Enterprise Value : -12.48M for Oct. 14, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 14, 2026 | -12.48M |
| October 13, 2026 | -12.49M |
| October 12, 2026 | -12.34M |
| October 09, 2026 | -12.25M |
| October 08, 2026 | -12.03M |
| October 07, 2026 | -11.38M |
| October 06, 2026 | -12.11M |
| October 05, 2026 | -12.05M |
| October 02, 2026 | -11.47M |
| October 01, 2026 | -11.41M |
| September 30, 2026 | -11.21M |
| September 29, 2026 | -11.18M |
| September 28, 2026 | -11.10M |
| September 25, 2026 | -11.04M |
| September 24, 2026 | -11.15M |
| September 23, 2026 | -10.97M |
| September 22, 2026 | -10.89M |
| September 21, 2026 | -10.89M |
| September 18, 2026 | -10.91M |
| September 17, 2026 | -11.05M |
| September 16, 2026 | -10.60M |
| September 15, 2026 | -10.60M |
| September 14, 2026 | -10.50M |
| September 11, 2026 | -10.53M |
| September 10, 2026 | -10.48M |
| Date | Value |
|---|---|
| September 09, 2026 | -10.38M |
| September 08, 2026 | -10.31M |
| September 04, 2026 | -10.33M |
| September 03, 2026 | -10.41M |
| September 02, 2026 | -10.26M |
| September 01, 2026 | -10.36M |
| August 31, 2026 | -10.38M |
| August 28, 2026 | -10.31M |
| August 27, 2026 | -10.02M |
| August 26, 2026 | -10.10M |
| August 25, 2026 | -10.33M |
| August 24, 2026 | -10.29M |
| August 21, 2026 | -10.29M |
| August 20, 2026 | -10.29M |
| August 19, 2026 | -10.26M |
| August 18, 2026 | -10.38M |
| August 17, 2026 | -10.38M |
| August 14, 2026 | -10.31M |
| August 13, 2026 | -10.19M |
| August 12, 2026 | -10.17M |
| August 11, 2026 | -10.12M |
| August 10, 2026 | -10.14M |
| August 07, 2026 | -10.12M |
| August 06, 2026 | -9.713M |
| August 05, 2026 | -9.880M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| ACADIA Pharmaceuticals, Inc. | 2.431B |
| Alnylam Pharmaceuticals, Inc. | 29.70B |
| Anika Therapeutics, Inc. | 257.84M |
| Savara, Inc. | 835.07M |
| Vericel Corp. | 1.992B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -1.564M |
| Revenue (Quarterly) | 9.264M |
| Total Expenses (Quarterly) | 10.83M |
| EPS Diluted (Quarterly) | -1.146 |
| Gross Profit Margin (Quarterly) | 25.35% |
| Profit Margin (Quarterly) | -16.88% |
| Earnings Yield | -4.21K% |
| Normalized Earnings Yield | -3775.93 |